Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Carraro, Dirce Maria ^a,e   Koike Folgueira, Maria Aparecida Azevedo ^b   Garcia Lisboa, Bianca Cristina ^a   Ribeiro Olivieri, Eloisa Helena ^a   Vitorino Krepischi, Ana Cristina ^a,e   de Carvalho, Alex Fiorini ^a   de Carvalho Mota, Louise Danielle ^a   Puga, Renato David ^a   do Socorro Maciel, Maria ^a   Michelli, Rodrigo Augusto Depieri ^c   de Lyra, Eduardo Carneiro ^d   Grosso, Stana Helena Giorgi ^d   Soares, Fernando Augusto ^a   de Souza Waddington Achatz, Maria Isabel Alves ^a,e   Brentani, Helena ^b   Moreira Filho, Carlos Alberto ^b   Brentani, Maria Mitzi ^b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d Inst Brasileiro de Controle Cancer   (Brazil)

^e National Institute of Science and Technology in Oncogenomics (INCITO)   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BRAZIL; BRAZILIAN; BRCA2 GENE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CHEK2 GENE; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; ETHNIC GROUP; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; ONSET AGE; PROTEIN EXPRESSION; SOMATIC ACQUIRED CHROMOSOMAL ALTERATION; TP53 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADULT; AGE OF ONSET; BRAZIL; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; INHERITANCE PATTERNS; PEDIGREE; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874562871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057581     Document Type: Article

References (50)

1. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, et al. (2005) Women age
2. Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, et al. (2008) BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci 5: 197-202.
3. Gentilini O, Botteri E, Rotmensz N, Toesca A, De Oliveira H, et al. (2010) Breast-conserving surgery in 201 very young patients (<35 years). Breast 19: 55-58.
4. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, et al. (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21: 1974-1981.
5. Peng R, Wang S, Shi Y, Liu D, Teng X, et al. (2011) Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: a retrospective matched case-control study. Breast 20: 568-573.
6. Ortega Jacome GP, Koifman RJ, Rego Monteiro GT, Koifman S, (2010) Environmental exposure and breast cancer among young women in Rio de Janeiro, Brazil. J Toxicol Environ Health A 73: 858-865.
7. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, et al. (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6: 194.
8. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330.
9. Han W, Kang SY, (2010) Society KBC (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119: 193-200.
10. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E, (2003) Breast cancer in young women: clinicopathological features and biological specificity. Breast 12: 247-250.
11. Fernandopulle SM, Cher-Siangang P, Tan PH, (2006) Breast carcinoma in women 35 years and younger: a pathological study. Pathology 38: 219-222.
12. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, et al. (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 1 18(5): 1341-51.
13. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, et al. (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13: 273-279.
14. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
15. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, et al. (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117: 1602-1611.
16. Lalloo F, Varley J, Moran A, Ellis D, O'dair L, et al. (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42: 1143-1150.
17. Fackenthal JD, Olopade OI, (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7: 937-948.
18. Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, et al. (2009) Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol 20: 1653-1659.
19. Walsh T, King MC, (2007) Ten genes for inherited breast cancer. Cancer Cell 11: 103-105.
20. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, et al. (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6: 782-789.
21. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, et al. (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90: 5-14.
22. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, et al. (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43: 867-876.
23. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, et al. (2003) Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 100: 2532-2537.
24. Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, et al. (2005) Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-7621.
25. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, et al. (2012) Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 14: R24.
26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
27. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, et al. (2006) Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res 12: 1693-1700.
28. Dutra MC, Rezende MA, de Andrade VP, Soares FA, Ribeiro MV, et al. (2009) [Immunophenotype and evolution of breast carcinomas: a comparison between very young and postmenopausal women]. Rev Bras Ginecol Obstet 31: 54-60.
29. Bacchi LM, Corpa M, Santos PP, Bacchi CE, Carvalho FM, (2010) Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. Breast 19: 137-141.
30. Carvalho LV, Pereira EM, Frappart L, Boniol M, Bernardo WM, et al. (2010) Molecular characterization of breast cancer in young Brazilian women. Rev Assoc Med Bras 56: 278-287.
31. Lourenço JJ VF, Bines J, Santos EM, Lasmar CAP, Costa CH, et al. (2004) BRCA1 mutations in Brazilian patients. Genetics and Molecular Biology 27: 500-504.
32. Figueiredo JC, Ennis M, Knight JA, McLaughlin JR, Hood N, et al. (2007) Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 105: 69-80.
33. Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A, et al. (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71: 165-170.
34. Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, et al. (2005) Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 43: 404-413.
35. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, et al. (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9: 86.
36. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, et al. (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130: 145-153.
37. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, et al. (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106: 1234-1238.
38. Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, et al. (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8: 563-567.
39. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, et al. (2010) Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 31: 143-150.
40. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, et al. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245: 96-102.
41. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
42. Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443.
43. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, et al. (2008) Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10: R87.
44. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
45. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
46. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P, (2010) Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10: 858-870.
47. Damiano L, Di Stefano P, Camacho Leal MP, Barba M, Mainiero F, et al. (2010) p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signaling in tumour cell scatter and proliferation. Oncogene 29(25): 3677-90.
48. Hayashi T, Arimura T, Itoh-Satoh M, Ueda K, Hohda S, et al. (2004) Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 44(11): 2192-20.
49. Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, et al. (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103: 349-353.
50. da Costa EC, Vargas FR, Moreira AS, Lourenço JJ, Caleffi M, et al. (2008) Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet 184: 62-66.